Kadimastem Ltd (TLV: KDST)

Market Cap	28.72M
Revenue (ttm)	n/a
Net Income (ttm)	-9.72M
Shares Out	4.19M
EPS (ttm)	-2.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2
Open	684.90
Previous Close	684.90
Day's Range	684.90 - 684.90
52-Week Range	430.00 - 933.00
Beta	0.43
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 28, 2024

About Kadimastem

Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was incorporated in 2008 and is based in Ness Ziona, Israel.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 12
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: KDST